Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 12 of 12

List	Outcome	Time frame
Primary	PFS as Determined by BICR	Up to approximately 6 years
Primary	OS Over the Whole Trial	Up to approximately 6 years
Secondary	PFS Determined by Investigator Assessment	Up to approximately 6 years
Secondary	Complete Response (CR) Rate	Up to approximately 6 years
Secondary	CR + non-CR/non-Progressive Disease (PD) Rate	Up to approximately 6 years
Secondary	Duration of Complete Response	Up to approximately 6 years
Secondary	PFS at 6 months, 1 year, 2 years	6 months, 1 year, 2 years
Secondary	OS at 6 months, 1 year, 2 years, 3 years	6 months, 1 year, 2 years, 3 years
Secondary	Time to Progression (TTP)	Up to approximately 6 years
Secondary	Number of Participants with Treatment-emergent Adverse Events (TEAEs)	Up to approximately 6 years
Secondary	Serum Concentration of Tarlatamab	Up to approximately 4 months
Secondary	Incidence of Anti-tarlatamab Antibody Formation	Up to approximately 1 year

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06117774/registered